Buy ($175)
Topics covered: The outlook for generics, The legality of authorized generics, The FDA approval process, Stocks to avoid., Stock recommendations, Patent challenges, Partnerships with Big Pharma, Options and earnings restatements, New product pipelines, Management performance, M&A Activity, Legal and regulatory outlook, Investor interest
or create an account with a social network.
or login using a social network
